| Latest Penwest Pharmaceuticals News Headlines |
| Date | Time | Source | |
| 02/15/2008 | 6:54PM | PRNUS | Accipiter Life Sciences Announces Nomination of Three Independent Director Candidates for Election to the Penwest Board at the 2
NEW YORK, Feb. 15 /PRNewswire/ -- Accipiter Life Sciences Fund, LP ("Accipiter Life Sciences"), announced today that it has nominated Gabe Hoffman, David Lohman and Eugene I. Davis for election to the Board of Directors of Penwest Pharmaceuticals Co. (the "Company") (NASDAQ:PPCO) at the Company's 2008 Annual Meeting... More...>> |
| 07/10/2007 | 7:00AM | PRNUS | WallSt.net (www.wallst.net ) Updates the Investment Community Through All-New Interviews with BPA, PPCO and NVAX
NEW YORK, July 10 /PRNewswire/ -- On June 19, Stephen Simes, CEO of Biosante Pharmaceuticals, Inc. (AMEX:BPA) (http://www.biosantepharma.com/ ) updated the investment community in an all-new interview with http://www.wallst.net/. Interview highlights include detailed discussions on the following topics:
-- the company's... More...>> |
| 06/15/2007 | 8:00AM | PRNUS | W. James O'Shea Named to Penwest Pharmaceuticals Board of Directors
DANBURY, Conn., June 15 /PRNewswire-FirstCall/ -- Penwest Pharmaceuticals Co. (NASDAQ:PPCO) announced today that W. James O'Shea has been named to the Company's Board of Directors.
Mr. O'Shea currently serves as Vice Chairman at Sepracor Inc. From October 1999 through March 2007, Mr. O'Shea served as President and... More...>> |
| 06/12/2007 | 8:31AM | PRNUS | Penwest Begins Dosing Phase IIa Clinical Study of Nalbuphine ER
DANBURY, Conn., June 12 /PRNewswire-FirstCall/ -- Penwest Pharmaceuticals Co. (NASDAQ:PPCO) announced today that it has begun dosing patients in its Phase IIa study to evaluate the analgesic efficacy of nalbuphine hydrochloride extended release tablet formulation (nalbuphine ER), a product the Company is developing... More...>> |
| 05/17/2007 | 4:30PM | PRNUS | Penwest to Participate in Upcoming Conferences
DANBURY, Conn., May 17 /PRNewswire-FirstCall/ -- Penwest Pharmaceuticals Co. (NASDAQ:PPCO) today announced that Jennifer Good, President and Chief Executive Officer of Penwest, will be presenting at the Bank of America 2007 Healthcare Conference which will be held at the Four Seasons Hotel in Las Vegas, Nevada. Ms... More...>> |
| 05/02/2007 | 10:30AM | PRNUS | Penwest Names Amale Hawi Senior Vice President, Pharmaceutical Development
DANBURY, Conn., May 2 /PRNewswire-FirstCall/ -- Penwest Pharmaceuticals Co. (NASDAQ:PPCO) today announced that Amale Hawi, Ph.D. has joined the Company as Senior Vice President, Pharmaceutical Development. Dr. Hawi will have primary responsibility for Penwest's preclinical and CMC drug development strategy, and will... More...>> |
| 04/26/2007 | 7:32AM | PRNUS | Penwest Reports First Quarter 2007 Financial Results
DANBURY, Conn., April 26 /PRNewswire-FirstCall/ -- Penwest Pharmaceuticals Co. (NASDAQ:PPCO) today announced its financial results for the first quarter ended March 31, 2007.
Total revenues for the first quarter of 2007 were $842,000 compared with $965,000 in the first quarter of 2006. The decrease reflects a reduction... More...>> |
| 04/25/2007 | 10:50AM | PRNUS | Penwest to Participate in Upcoming Conferences
DANBURY, Conn., April 25 /PRNewswire-FirstCall/ -- Penwest Pharmaceuticals Co. (NASDAQ:PPCO) today announced that Jennifer Good, President and Chief Executive Officer will be presenting at the Deutsche Bank Healthcare conference on May 3, 2007 at 10:30 a.m. Eastern Daylight Time. The conference will be held at the... More...>> |
| 04/12/2007 | 10:43AM | PRNUS | Penwest First Quarter 2007 Financial Results Conference Call
DANBURY, Conn., April 12 /PRNewswire-FirstCall/ -- Penwest Pharmaceuticals Co. (NASDAQ:PPCO) will conduct a conference call on Thursday, April 26, at 11:00 a.m. EDT to review its financial results for the first quarter of 2007, which will be released earlier that day. Operational developments and financial outlook... More...>> |
| 03/27/2007 | 4:30PM | PRNUS | Penwest Enters Into Collaboration Agreement With PII
Expands Licensing Strategy for Its Drug Delivery Technologies
DANBURY, Conn., March 27 /PRNewswire-FirstCall/ -- Penwest Pharmaceuticals Co. (NASDAQ:PPCO) announced today that it has signed a collaboration agreement with Pharmaceutics International Inc. (PII) under which PII has agreed to conduct formulation work for... More...>> |
| 03/15/2007 | 5:10PM | PRNUS | Penwest Confirms Patent and Trademark Office Action on Oxymorphone Patent Application
DANBURY, Conn., March 15 /PRNewswire-FirstCall/ -- Penwest Pharmaceuticals Co. (NASDAQ:PPCO) today confirmed that the U.S. Patent and Trademark Office (PTO) has posted on its website an indication that a final rejection of Penwest's patent application claiming the sustained release formulations of Oxymorphone will be... More...>> |
| 03/13/2007 | 9:48AM | PRNUS | Penwest Announces $24 Million Credit Facility
DANBURY, Conn., March 13 /PRNewswire-FirstCall/ -- Penwest Pharmaceuticals Co. (NASDAQ:PPCO) announced today that it has established a $24 million Senior Secured Credit Facility through Merrill Lynch Capital, a division of Merrill Lynch Business Financial Services Inc. The Company expects that this new facility will... More...>> |
| 02/28/2007 | 7:31AM | PRNUS | Penwest Reports Fourth Quarter and Year End 2006 Financial Results
DANBURY, Conn., Feb. 28 /PRNewswire-FirstCall/ -- Penwest Pharmaceuticals Co. (NASDAQ:PPCO) today announced its financial results for the fourth quarter and full year ended December 31, 2006.
Fourth Quarter
Total revenues for the fourth quarter of 2006 were $739,000 compared with $931,000 in the fourth quarter of... More...>> |
| 02/22/2007 | 10:30AM | PRNUS | Penwest To Participate In Upcoming Conferences
DANBURY, Conn., Feb. 22 /PRNewswire-FirstCall/ -- Penwest Pharmaceuticals Co. (NASDAQ:PPCO) today announced that Jennifer L. Good, President and Chief Executive Officer, will be presenting at Susquehanna Financial Group's SIGnificant Investment Options in Healthcare Conference on Thursday, March 1, 2007, at 11:00 a.m... More...>> |
| 02/15/2007 | 10:30AM | PRNUS | Penwest Fourth Quarter and Year End 2006 Financial Results Conference Call
DANBURY, Conn., Feb. 15 /PRNewswire-FirstCall/ -- Penwest Pharmaceuticals Co. (NASDAQ:PPCO) will conduct a conference call on Wednesday, February 28, at 11:00 a.m. EST to review its financial results for the fourth quarter and year end of 2006, which will be released earlier that day. Operational developments and financial... More...>> |
| 01/29/2007 | 4:50PM | PRNUS | Penwest to Present at 2007 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
DANBURY, Conn., Jan. 29 /PRNewswire-FirstCall/ -- Penwest Pharmaceuticals Co. (NASDAQ:PPCO) today announced that Jennifer Good, President and Chief Executive Officer of Penwest, is scheduled to present at the 2007 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference. The conference is being... More...>> |
| 01/26/2007 | 4:21PM | PRNUS | Jennifer Good Honored by the Connecticut Technology Council at the 2007 Women of Innovation Awards
DANBURY, Conn., Jan. 26 /PRNewswire-FirstCall/ -- Penwest Pharmaceuticals Co. (NASDAQ:PPCO) today announced that President and Chief Executive Officer Jennifer L. Good was honored with the prestigious Small Business Innovation and Leadership Award at the Connecticut Technology Council's third annual Women of Innovation... More...>> |
| 01/19/2007 | 7:18AM | PRNUS | Penwest Begins Next Study in Development of Nalbuphine ER
DANBURY, Conn., Jan. 19 /PRNewswire-FirstCall/ -- Penwest Pharmaceuticals Co. (NASDAQ:PPCO) today announced that it has begun a Phase I safety study on a nalbuphine hydrochloride extended release tablet formulation (Nalbuphine ER) that the Company is developing for the treatment of pain.
Nalbuphine ER is a controlled... More...>> |
| 01/08/2007 | 7:01AM | PRNUS | Endo and Penwest Agree to Amend Opana(R) ER Contract
CHADDS FORD, Pa. and DANBURY, Conn., Jan. 8 /PRNewswire-FirstCall/ -- Endo Pharmaceuticals Holdings Inc. (NASDAQ:ENDP) and Penwest Pharmaceuticals Co. (NASDAQ:PPCO) today announced an amendment to the contract governing the companies' collaboration for Opana(R) ER (oxymorphone HCl) extended-release tablets CII. The... More...>> |
| 01/04/2007 | 4:05PM | PRNUS | David P. Meeker, M.D. Named to Penwest Pharmaceuticals Board Of Directors
DANBURY, Conn., Jan. 4 /PRNewswire-FirstCall/ -- Penwest Pharmaceuticals Co. (NASDAQ:PPCO) today announced that David P. Meeker, M.D., President of the LSD (Lysosomal Storage Diseases) Therapeutics business unit of Genzyme Corporation, has been named to the company's Board of Directors.
During his leadership of the... More...>> |